The 60-second version of Max India Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
No clear supporting case emerges from the available numbers.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹201 Cr | ₹176 Cr | ₹145 Cr | ₹191 Cr | -1.8% |
| EBITDA | ₹19 Cr | -₹33 Cr | -₹99 Cr | -₹87 Cr | — |
| EBITDA Margin | 9.6% | -19.0% | -67.7% | -45.6% | — |
| PAT (Net Profit) | -₹10 Cr | -₹56 Cr | -₹140 Cr | -₹122 Cr | — |
| EPS | ₹-2.06 | ₹-12.36 | ₹-31.55 | ₹-23.85 | — |
| ROE | -1.9% | -11.5% | -39.1% | -29.8% | — |
| ROCE | 0.5% | -8.2% | -27.9% | -21.1% | — |
| Total Debt | ₹45 Cr | ₹44 Cr | ₹102 Cr | ₹96 Cr | +28.5% |
| Free Cash Flow | ₹66 Cr | -₹131 Cr | -₹163 Cr | -₹146 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| APOLLO HOSPITALS ENTER. L | 54.3x | 22.0% |
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| CIPLA LTD | 31.8x | 9.8% |
Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 6 high-severity red flags sit above this conclusion and should be read first.